Harnessing the alarmin HMGN1 for anticancer therapy

De Yang; Michael Bustin; Joost J Oppenheim

doi:10.2217/imt.15.76

Harnessing the alarmin HMGN1 for anticancer therapy

Immunotherapy. 2015;7(11):1129-31. doi: 10.2217/imt.15.76. Epub 2015 Nov 16.

Authors

De Yang¹, Michael Bustin², Joost J Oppenheim¹

Affiliations

¹ Laboratory of Molecular Immunoregulation, Cancer & Inflammation Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA.
² Protein Section, Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute at Bethesda, Bethesda, MD 20892, USA.

PMID: 26567750
DOI: 10.2217/imt.15.76

No abstract available

Keywords: G protein-coupled receptor; HMG protein; HMGN1; TLR4; alarmin; antitumor immunity; cancer therapy; chromatin modification; dendritic cell; gene regulation.

Publication types

Editorial
Research Support, N.I.H., Extramural
Review

MeSH terms

Alarmins / genetics
Alarmins / immunology
Alarmins / metabolism*
Animals
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Dendritic Cells / physiology*
Gene Expression Regulation, Neoplastic
HMGN1 Protein / genetics
HMGN1 Protein / immunology
HMGN1 Protein / metabolism*
Humans
Immunomodulation
Lymphocyte Activation
Neoplasms / immunology*
Neoplasms / therapy
Th1 Cells / immunology*
Tumor Microenvironment

Substances

Alarmins
HMGN1 Protein